CN101351227A - 指甲用医药组合物 - Google Patents
指甲用医药组合物 Download PDFInfo
- Publication number
- CN101351227A CN101351227A CNA2006800496424A CN200680049642A CN101351227A CN 101351227 A CN101351227 A CN 101351227A CN A2006800496424 A CNA2006800496424 A CN A2006800496424A CN 200680049642 A CN200680049642 A CN 200680049642A CN 101351227 A CN101351227 A CN 101351227A
- Authority
- CN
- China
- Prior art keywords
- nail
- pharmaceutical composition
- application
- fingernail
- antifungal agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 79
- 229940121375 antifungal agent Drugs 0.000 claims abstract description 59
- 239000003429 antifungal agent Substances 0.000 claims abstract description 56
- 210000000282 nail Anatomy 0.000 claims description 80
- 210000004905 finger nail Anatomy 0.000 claims description 56
- -1 alkyl pyrrolidone Chemical compound 0.000 claims description 44
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 22
- 239000000839 emulsion Substances 0.000 claims description 19
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 18
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 15
- 150000003851 azoles Chemical class 0.000 claims description 15
- 229920002521 macromolecule Polymers 0.000 claims description 13
- 239000000499 gel Substances 0.000 claims description 12
- 229920002125 Sokalan® Polymers 0.000 claims description 10
- 238000004132 cross linking Methods 0.000 claims description 9
- 239000004744 fabric Substances 0.000 claims description 8
- 239000011248 coating agent Substances 0.000 claims description 7
- 238000000576 coating method Methods 0.000 claims description 7
- 239000004584 polyacrylic acid Substances 0.000 claims description 7
- 150000005846 sugar alcohols Polymers 0.000 claims description 7
- 239000002202 Polyethylene glycol Substances 0.000 claims description 6
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 6
- 235000011187 glycerol Nutrition 0.000 claims description 6
- 229920001223 polyethylene glycol Polymers 0.000 claims description 6
- OCAPBUJLXMYKEJ-UHFFFAOYSA-N 1-[biphenyl-4-yl(phenyl)methyl]imidazole Chemical compound C1=NC=CN1C(C=1C=CC(=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 OCAPBUJLXMYKEJ-UHFFFAOYSA-N 0.000 claims description 5
- 239000012790 adhesive layer Substances 0.000 claims description 5
- 229960002206 bifonazole Drugs 0.000 claims description 5
- 239000012744 reinforcing agent Substances 0.000 claims description 5
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 claims description 4
- MQHLMHIZUIDKOO-OKZBNKHCSA-N (2R,6S)-2,6-dimethyl-4-[(2S)-2-methyl-3-[4-(2-methylbutan-2-yl)phenyl]propyl]morpholine Chemical compound C1=CC(C(C)(C)CC)=CC=C1C[C@H](C)CN1C[C@@H](C)O[C@@H](C)C1 MQHLMHIZUIDKOO-OKZBNKHCSA-N 0.000 claims description 4
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 4
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 4
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 4
- 229960003204 amorolfine Drugs 0.000 claims description 4
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 4
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 4
- 229960004022 clotrimazole Drugs 0.000 claims description 4
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 claims description 4
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 claims description 4
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 4
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 4
- VWOIKFDZQQLJBJ-DTQAZKPQSA-N neticonazole Chemical compound CCCCCOC1=CC=CC=C1\C(=C/SC)N1C=NC=C1 VWOIKFDZQQLJBJ-DTQAZKPQSA-N 0.000 claims description 4
- 229950010757 neticonazole Drugs 0.000 claims description 4
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 claims description 3
- QXHHHPZILQDDPS-UHFFFAOYSA-N 1-{2-[(2-chloro-3-thienyl)methoxy]-2-(2,4-dichlorophenyl)ethyl}imidazole Chemical compound S1C=CC(COC(CN2C=NC=C2)C=2C(=CC(Cl)=CC=2)Cl)=C1Cl QXHHHPZILQDDPS-UHFFFAOYSA-N 0.000 claims description 3
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 3
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 claims description 3
- WHPAGCJNPTUGGD-UHFFFAOYSA-N Croconazole Chemical compound ClC1=CC=CC(COC=2C(=CC=CC=2)C(=C)N2C=NC=C2)=C1 WHPAGCJNPTUGGD-UHFFFAOYSA-N 0.000 claims description 3
- 229960002042 croconazole Drugs 0.000 claims description 3
- 150000002148 esters Chemical class 0.000 claims description 3
- 239000003205 fragrance Substances 0.000 claims description 3
- 229960004130 itraconazole Drugs 0.000 claims description 3
- 229960004125 ketoconazole Drugs 0.000 claims description 3
- 229960000988 nystatin Drugs 0.000 claims description 3
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 claims description 3
- 229960004214 tioconazole Drugs 0.000 claims description 3
- 229960004880 tolnaftate Drugs 0.000 claims description 3
- FUSNMLFNXJSCDI-UHFFFAOYSA-N tolnaftate Chemical compound C=1C=C2C=CC=CC2=CC=1OC(=S)N(C)C1=CC=CC(C)=C1 FUSNMLFNXJSCDI-UHFFFAOYSA-N 0.000 claims description 3
- MPIPASJGOJYODL-SFHVURJKSA-N (R)-isoconazole Chemical compound ClC1=CC(Cl)=CC=C1[C@@H](OCC=1C(=CC=CC=1Cl)Cl)CN1C=NC=C1 MPIPASJGOJYODL-SFHVURJKSA-N 0.000 claims description 2
- AFNXATANNDIXLG-SFHVURJKSA-N 1-[(2r)-2-[(4-chlorophenyl)methylsulfanyl]-2-(2,4-dichlorophenyl)ethyl]imidazole Chemical compound C1=CC(Cl)=CC=C1CS[C@H](C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 AFNXATANNDIXLG-SFHVURJKSA-N 0.000 claims description 2
- UGAQMGXCNYQXHP-UHFFFAOYSA-N 1-ethoxypyrrolidin-2-one Chemical compound CCON1CCCC1=O UGAQMGXCNYQXHP-UHFFFAOYSA-N 0.000 claims description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 2
- LEZWWPYKPKIXLL-UHFFFAOYSA-N 1-{2-(4-chlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl}imidazole Chemical compound C1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 LEZWWPYKPKIXLL-UHFFFAOYSA-N 0.000 claims description 2
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 claims description 2
- 102000011632 Caseins Human genes 0.000 claims description 2
- 108010076119 Caseins Proteins 0.000 claims description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 2
- 108010010803 Gelatin Proteins 0.000 claims description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 2
- 229920003091 Methocel™ Polymers 0.000 claims description 2
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 claims description 2
- WPPOGHDFAVQKLN-UHFFFAOYSA-N N-Octyl-2-pyrrolidone Chemical compound CCCCCCCCN1CCCC1=O WPPOGHDFAVQKLN-UHFFFAOYSA-N 0.000 claims description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 2
- 229920002472 Starch Polymers 0.000 claims description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 2
- 239000011243 crosslinked material Substances 0.000 claims description 2
- GPLRAVKSCUXZTP-UHFFFAOYSA-N diglycerol Chemical compound OCC(O)COCC(O)CO GPLRAVKSCUXZTP-UHFFFAOYSA-N 0.000 claims description 2
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 claims description 2
- 229960003913 econazole Drugs 0.000 claims description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 2
- 239000008273 gelatin Substances 0.000 claims description 2
- 229920000159 gelatin Polymers 0.000 claims description 2
- 235000019322 gelatine Nutrition 0.000 claims description 2
- 235000011852 gelatine desserts Nutrition 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 2
- 229940071826 hydroxyethyl cellulose Drugs 0.000 claims description 2
- 229960004849 isoconazole Drugs 0.000 claims description 2
- 229910052751 metal Inorganic materials 0.000 claims description 2
- 239000002184 metal Substances 0.000 claims description 2
- 229920000609 methyl cellulose Polymers 0.000 claims description 2
- 239000001923 methylcellulose Substances 0.000 claims description 2
- 235000010981 methylcellulose Nutrition 0.000 claims description 2
- 229960002509 miconazole Drugs 0.000 claims description 2
- 229960003483 oxiconazole Drugs 0.000 claims description 2
- QRJJEGAJXVEBNE-MOHJPFBDSA-N oxiconazole Chemical compound ClC1=CC(Cl)=CC=C1CO\N=C(C=1C(=CC(Cl)=CC=1)Cl)\CN1C=NC=C1 QRJJEGAJXVEBNE-MOHJPFBDSA-N 0.000 claims description 2
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 claims description 2
- 229920001451 polypropylene glycol Polymers 0.000 claims description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 2
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 claims description 2
- QGKLPGKXAVVPOJ-UHFFFAOYSA-N pyrrolidin-3-one Chemical compound O=C1CCNC1 QGKLPGKXAVVPOJ-UHFFFAOYSA-N 0.000 claims description 2
- 235000010413 sodium alginate Nutrition 0.000 claims description 2
- 239000000661 sodium alginate Substances 0.000 claims description 2
- 229940005550 sodium alginate Drugs 0.000 claims description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 2
- 229940080237 sodium caseinate Drugs 0.000 claims description 2
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 claims description 2
- 239000000600 sorbitol Substances 0.000 claims description 2
- 239000008107 starch Substances 0.000 claims description 2
- 235000019698 starch Nutrition 0.000 claims description 2
- 229960002607 sulconazole Drugs 0.000 claims description 2
- 229960002722 terbinafine Drugs 0.000 claims description 2
- DOMXUEMWDBAQBQ-WEVVVXLNSA-N terbinafine Chemical compound C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 DOMXUEMWDBAQBQ-WEVVVXLNSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims 1
- 241001597008 Nomeidae Species 0.000 claims 1
- XJRBAMWJDBPFIM-UHFFFAOYSA-N methyl vinyl ether Chemical compound COC=C XJRBAMWJDBPFIM-UHFFFAOYSA-N 0.000 claims 1
- 238000002360 preparation method Methods 0.000 abstract description 12
- 230000000694 effects Effects 0.000 abstract description 11
- 208000010195 Onychomycosis Diseases 0.000 abstract description 10
- 201000005882 tinea unguium Diseases 0.000 abstract description 10
- 230000001225 therapeutic effect Effects 0.000 abstract description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 6
- 201000010099 disease Diseases 0.000 abstract description 5
- 241000222120 Candida <Saccharomycetales> Species 0.000 abstract 1
- 239000000203 mixture Substances 0.000 description 25
- 239000003795 chemical substances by application Substances 0.000 description 22
- 230000035699 permeability Effects 0.000 description 17
- 238000012360 testing method Methods 0.000 description 17
- 239000003814 drug Substances 0.000 description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
- 238000000034 method Methods 0.000 description 12
- 238000004519 manufacturing process Methods 0.000 description 11
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Natural products C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 10
- 239000000463 material Substances 0.000 description 9
- 239000003431 cross linking reagent Substances 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 239000010408 film Substances 0.000 description 8
- 239000000835 fiber Substances 0.000 description 7
- 239000004745 nonwoven fabric Substances 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 6
- 239000004743 Polypropylene Substances 0.000 description 5
- 238000009825 accumulation Methods 0.000 description 5
- 229920001577 copolymer Polymers 0.000 description 5
- 229920001155 polypropylene Polymers 0.000 description 5
- 239000002994 raw material Substances 0.000 description 5
- 239000004698 Polyethylene Substances 0.000 description 4
- 230000000843 anti-fungal effect Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 239000002674 ointment Substances 0.000 description 4
- 229920000573 polyethylene Polymers 0.000 description 4
- 229920000139 polyethylene terephthalate Polymers 0.000 description 4
- 239000005020 polyethylene terephthalate Substances 0.000 description 4
- 239000008213 purified water Substances 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 239000010409 thin film Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 241000233866 Fungi Species 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000002421 anti-septic effect Effects 0.000 description 3
- 239000004202 carbamide Substances 0.000 description 3
- 235000013877 carbamide Nutrition 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 238000004321 preservation Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- LVYLCBNXHHHPSB-UHFFFAOYSA-N 2-hydroxyethyl salicylate Chemical compound OCCOC(=O)C1=CC=CC=C1O LVYLCBNXHHHPSB-UHFFFAOYSA-N 0.000 description 2
- 206010008190 Cerebrovascular accident Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- IIUZTXTZRGLYTI-UHFFFAOYSA-N Dihydrogriseofulvin Natural products COC1CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 IIUZTXTZRGLYTI-UHFFFAOYSA-N 0.000 description 2
- 239000001856 Ethyl cellulose Substances 0.000 description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
- UXWOXTQWVMFRSE-UHFFFAOYSA-N Griseoviridin Natural products O=C1OC(C)CC=C(C(NCC=CC=CC(O)CC(O)C2)=O)SCC1NC(=O)C1=COC2=N1 UXWOXTQWVMFRSE-UHFFFAOYSA-N 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- 208000031888 Mycoses Diseases 0.000 description 2
- DDUHZTYCFQRHIY-UHFFFAOYSA-N Negwer: 6874 Natural products COC1=CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-UHFFFAOYSA-N 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 229920002396 Polyurea Polymers 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- BZHJMEDXRYGGRV-UHFFFAOYSA-N Vinyl chloride Chemical compound ClC=C BZHJMEDXRYGGRV-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 150000001399 aluminium compounds Chemical class 0.000 description 2
- 230000001857 anti-mycotic effect Effects 0.000 description 2
- 239000002543 antimycotic Substances 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- WERYXYBDKMZEQL-UHFFFAOYSA-N butane-1,4-diol Chemical compound OCCCCO WERYXYBDKMZEQL-UHFFFAOYSA-N 0.000 description 2
- 229920002301 cellulose acetate Polymers 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 235000019325 ethyl cellulose Nutrition 0.000 description 2
- 229920001249 ethyl cellulose Polymers 0.000 description 2
- 239000005038 ethylene vinyl acetate Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000003811 finger Anatomy 0.000 description 2
- 238000005187 foaming Methods 0.000 description 2
- 229960002867 griseofulvin Drugs 0.000 description 2
- DDUHZTYCFQRHIY-RBHXEPJQSA-N griseofulvin Chemical compound COC1=CC(=O)C[C@@H](C)[C@@]11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-RBHXEPJQSA-N 0.000 description 2
- 210000004247 hand Anatomy 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N isopropyl alcohol Natural products CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 208000026721 nail disease Diseases 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 210000002706 plastid Anatomy 0.000 description 2
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- 229920006267 polyester film Polymers 0.000 description 2
- 239000004814 polyurethane Substances 0.000 description 2
- 229920002635 polyurethane Polymers 0.000 description 2
- 229920006264 polyurethane film Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- QJBZDBLBQWFTPZ-UHFFFAOYSA-N pyrrolnitrin Chemical compound [O-][N+](=O)C1=C(Cl)C=CC=C1C1=CNC=C1Cl QJBZDBLBQWFTPZ-UHFFFAOYSA-N 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 229910052710 silicon Inorganic materials 0.000 description 2
- 239000010703 silicon Substances 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 235000013599 spices Nutrition 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 210000003813 thumb Anatomy 0.000 description 2
- 210000004906 toe nail Anatomy 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- MCCACAIVAXEFAL-UHFFFAOYSA-N 1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole;nitric acid Chemical compound O[N+]([O-])=O.ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 MCCACAIVAXEFAL-UHFFFAOYSA-N 0.000 description 1
- NNGQLSIGRSTLLU-UHFFFAOYSA-N 1-[2-(2,4-dichlorophenyl)-2-[(2,6-dichlorophenyl)methoxy]ethyl]imidazole;nitric acid Chemical compound O[N+]([O-])=O.ClC1=CC(Cl)=CC=C1C(OCC=1C(=CC=CC=1Cl)Cl)CN1C=NC=C1 NNGQLSIGRSTLLU-UHFFFAOYSA-N 0.000 description 1
- FRPZMMHWLSIFAZ-UHFFFAOYSA-N 10-undecenoic acid Chemical compound OC(=O)CCCCCCCCC=C FRPZMMHWLSIFAZ-UHFFFAOYSA-N 0.000 description 1
- ZEMPKEQAKRGZGQ-AAKVHIHISA-N 2,3-bis[[(z)-12-hydroxyoctadec-9-enoyl]oxy]propyl (z)-12-hydroxyoctadec-9-enoate Chemical class CCCCCCC(O)C\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CC(O)CCCCCC)COC(=O)CCCCCCC\C=C/CC(O)CCCCCC ZEMPKEQAKRGZGQ-AAKVHIHISA-N 0.000 description 1
- MBRHNTMUYWQHMR-UHFFFAOYSA-N 2-aminoethanol;6-cyclohexyl-1-hydroxy-4-methylpyridin-2-one Chemical compound NCCO.ON1C(=O)C=C(C)C=C1C1CCCCC1 MBRHNTMUYWQHMR-UHFFFAOYSA-N 0.000 description 1
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
- SODWJACROGQSMM-UHFFFAOYSA-N 5,6,7,8-tetrahydronaphthalen-1-amine Chemical compound C1CCCC2=C1C=CC=C2N SODWJACROGQSMM-UHFFFAOYSA-N 0.000 description 1
- 229920002955 Art silk Polymers 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 206010007134 Candida infections Diseases 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- ONKUXPIBXRRIDU-UHFFFAOYSA-N Diethyl decanedioate Chemical compound CCOC(=O)CCCCCCCCC(=O)OCC ONKUXPIBXRRIDU-UHFFFAOYSA-N 0.000 description 1
- 206010013710 Drug interaction Diseases 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- VPHPQNGOVQYUMG-UHFFFAOYSA-N Liranaftate Chemical compound COC1=CC=CC(N(C)C(=S)OC=2C=C3CCCCC3=CC=2)=N1 VPHPQNGOVQYUMG-UHFFFAOYSA-N 0.000 description 1
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 241000978776 Senegalia senegal Species 0.000 description 1
- UGGAILYEBCSZIV-ITJSPEIASA-N Siccanin Chemical compound C1CCC(C)(C)[C@@H]2CC[C@]3(C)OC4=CC(C)=CC(O)=C4[C@H]4[C@@H]3[C@@]21CO4 UGGAILYEBCSZIV-ITJSPEIASA-N 0.000 description 1
- UGGAILYEBCSZIV-UHFFFAOYSA-N Siccanin Natural products C1CCC(C)(C)C2CCC3(C)OC4=CC(C)=CC(O)=C4C4C3C21CO4 UGGAILYEBCSZIV-UHFFFAOYSA-N 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CRKGMGQUHDNAPB-UHFFFAOYSA-N Sulconazole nitrate Chemical compound O[N+]([O-])=O.C1=CC(Cl)=CC=C1CSC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 CRKGMGQUHDNAPB-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 208000002474 Tinea Diseases 0.000 description 1
- 241000130764 Tinea Species 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 239000003522 acrylic cement Substances 0.000 description 1
- 125000005250 alkyl acrylate group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000000305 astragalus gummifer gum Substances 0.000 description 1
- BESJRHHIPGWPTC-UHFFFAOYSA-N azane;copper Chemical compound N.[Cu] BESJRHHIPGWPTC-UHFFFAOYSA-N 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 150000003939 benzylamines Chemical class 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 229940043430 calcium compound Drugs 0.000 description 1
- 150000001674 calcium compounds Chemical class 0.000 description 1
- 201000003984 candidiasis Diseases 0.000 description 1
- KHAVLLBUVKBTBG-UHFFFAOYSA-N caproleic acid Natural products OC(=O)CCCCCCCC=C KHAVLLBUVKBTBG-UHFFFAOYSA-N 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229960004375 ciclopirox olamine Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000003851 corona treatment Methods 0.000 description 1
- DNTGGZPQPQTDQF-XBXARRHUSA-N crotamiton Chemical compound C/C=C/C(=O)N(CC)C1=CC=CC=C1C DNTGGZPQPQTDQF-XBXARRHUSA-N 0.000 description 1
- 229960003338 crotamiton Drugs 0.000 description 1
- 230000000254 damaging effect Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 229960003645 econazole nitrate Drugs 0.000 description 1
- 238000004049 embossing Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 238000001879 gelation Methods 0.000 description 1
- 229960002389 glycol salicylate Drugs 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 210000000003 hoof Anatomy 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229950010148 liranaftate Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 229950007687 macrogol ester Drugs 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- 150000002681 magnesium compounds Chemical class 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 125000005395 methacrylic acid group Chemical group 0.000 description 1
- 229960005040 miconazole nitrate Drugs 0.000 description 1
- 150000002780 morpholines Chemical class 0.000 description 1
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 229960004313 naftifine Drugs 0.000 description 1
- OZGNYLLQHRPOBR-DHZHZOJOSA-N naftifine Chemical compound C=1C=CC2=CC=CC=C2C=1CN(C)C\C=C\C1=CC=CC=C1 OZGNYLLQHRPOBR-DHZHZOJOSA-N 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 229940074355 nitric acid Drugs 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- WVNOAGNOIPTWPT-NDUABGMUSA-N oxiconazole nitrate Chemical compound O[N+]([O-])=O.ClC1=CC(Cl)=CC=C1CO\N=C(C=1C(=CC(Cl)=CC=1)Cl)/CN1C=NC=C1 WVNOAGNOIPTWPT-NDUABGMUSA-N 0.000 description 1
- 229960002894 oxiconazole nitrate Drugs 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 150000004291 polyenes Chemical class 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 229960002132 pyrrolnitrin Drugs 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 229950008379 siccanin Drugs 0.000 description 1
- 150000003376 silicon Chemical class 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229960004718 sulconazole nitrate Drugs 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 150000003560 thiocarbamic acids Chemical class 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- 239000002966 varnish Substances 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000011276 wood tar Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
- A61K9/7061—Polyacrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/02—Adhesive bandages or dressings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/10—Bandages or dressings; Absorbent pads specially adapted for fingers, hands, or arms; Finger-stalls; Nail-protectors
- A61F13/104—Bandages or dressings; Absorbent pads specially adapted for fingers, hands, or arms; Finger-stalls; Nail-protectors for the hands or fingers
- A61F13/105—Bandages or dressings; Absorbent pads specially adapted for fingers, hands, or arms; Finger-stalls; Nail-protectors for the hands or fingers for the fingers; Finger-stalls; Nail-protectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F2013/00361—Plasters
- A61F2013/00902—Plasters containing means
- A61F2013/00906—Plasters containing means for transcutaneous or transdermal drugs application
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Vascular Medicine (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Anesthesiology (AREA)
- Hematology (AREA)
Abstract
本发明的目的在于提供一种新的外用剂,现有的外用剂均不能实现其治疗效果,其对指甲的药物渗透性优异,可以充分发挥抗真菌药的效果,对指甲真菌症、指甲念珠菌症等疾病的治疗、特别是对甲癣的治疗有效。一种指甲用医药组合物,其特征在于,含有抗真菌药、烷基吡咯烷酮或其衍生物和交联型含水凝胶。
Description
技术领域
本发明涉及一种可以充分发挥抗真菌药效果的、并对指甲富于药物渗透性的指甲用医药组合物。
背景技术
甲癣是指甲上的真菌感染症,作为难治性的疾病而被公知。现在,作为甲癣的治疗方法,通过外用剂或口服剂进行治疗,不过,通过口服剂治疗存在副作用或药物相互作用的问题,因此不能进行治疗的患者也很多,对于这样的患者,通过外用剂进行治疗。不过现状是:现在市售的外用剂,由于对指甲的渗透性低,所以不能得到充分的治疗效果。由于可以简单地涂布在指甲上,所以作为指甲真菌症的治疗用制剂,开始研究甲涂剂和修甲制剂等被膜形成型组合物。
不过,像这样的被膜形成型组合物,为了得到被膜强度或耐水性而使用水不溶性的被膜形成剂作为被膜形成物质,所以涂布在指甲时存在的问题是:从形成在涂布面上的被膜中释放出抗真菌药和对指甲的渗透不充分。进而也存在着组合物中的丙酮、乙酸乙酯、甲苯等有机溶剂使指甲脱水、硬化,从而使抗真菌药对指甲的渗透性降低的问题。
另一方面,已知含有亲水性被膜形成物质、抗真菌药和水的被膜形成性抗真菌药组合物(专利文献1)。不过,该组合物的含水率为全部组合物的3~10%,由于含水率低,对指甲的药物渗透性低。因此通过该组合物,难以使抗真菌药渗透到指甲上,也不能充分发挥其效果。
另外,坪井等报告:调制含有40%尿素的抗真菌药乳膏,将涂布有该乳膏的指甲用聚氯乙烯膜包覆,利用该密封疗法使指甲水合(非专利文献1)的方法是有效的。不过由于含有40%尿素的药膏的稳定性和治疗方法繁杂,所以并不能称为通用性的治疗方法。
进而,已知由于指甲与皮肤角质层比,对药物透过性给与影响的脂质成分含量明显少,所以在指甲的治疗用制剂上,通常的皮肤用抗真菌药难于直接应用,并且已知为了有效地进行甲癣的药物治疗,需要提高药物的水溶解度(非专利文献2)。
作为提高药物水溶解度的技术,例如将水难溶性的奈康唑做成盐酸盐来提高水溶解度,含有其和碱性物质的指甲用抗真菌外用剂已被公知(专利文献2)。不过并不是哪一种抗真菌药都能做成盐酸盐来提高水溶解度,这也不是一种通用的技术。
另一方面,作为将水难溶性的抗真菌药用于指甲治疗用制剂的技术,公知的有,例如在指甲上涂布由乙醇、水和N-甲基吡咯烷酮构成的前处理液,使药剂的透过性提高后,涂布由凝胶基剂和抗真菌药氟康唑构成的指甲用组合物的方法(专利文献3)。不过该方法中存在必须分两次涂布药剂的繁杂性,另外,用于该方法的前处理液乙醇含量高,也存在着保存稳定性的问题。
另外,公知的是将水难溶性的抗真菌药灰黄霉素溶解于N-甲基-2-吡咯烷酮的组合物(专利文献4)。不过该组合物是以高浓度含有乙醇、丙酮等有机溶剂或N-甲基-2-吡咯烷酮的物质,存在稳定性和刺激性方面的问题。
专利文献1:日本特开平10-152433号公报
专利文献2:日本特开2004-83439号公报
专利文献3:日本特表2004-529923号公报
专利文献4:美国专利3,932,653号
非专利文献1:日本医真菌学会志,vol.39,11-16,1998
非专利文献2:フアルマシア,vol.35,569-573,1999
发明内容
发明所要解决的问题
如上所述,现有的用于指甲的外用剂任何一种的治疗效果都不能满意,希望开发出对指甲的药物渗透性优异、可充分发挥抗真菌药效果的指甲真菌症用的新的外用剂,本发明的课题是提供一种这样的外用剂。
解决问题的方法
本发明人们为解决上述课题反复精心研究,结果发现包含在烷基吡咯烷酮或其衍生物和交联型含水凝胶中的指甲用医药组合物,对指甲的药物渗透性优异,可以充分发挥抗真菌药的效果,以及若将该指甲用医药组合物用于贴剂,则进一步提高便利性,并完成了本发明。
即,本发明提供一种指甲用医药组合物,其特征在于,含有抗真菌药、烷基吡咯烷酮或其衍生物和交联型含水凝胶。
另外,本发明还提供一种将上述指甲用医药组合物在支持体上涂布、展开而形成的指甲用贴剂。
发明效果
本发明的指甲用医药组合物,提高对指甲的药物渗透性,可以充分发挥抗真菌药的效果。另外,本发明的指甲用医药组合物由于不含有乙醇等,所以即使长期保存也可以稳定地保持药剂。
因此,本发明的指甲用医药组合物,被期待作为在甲癣等的治疗上发挥效果的外用剂进行利用。
附图说明
图1是显示试验例1中经过时间与抗真菌药向指甲中的累积透过量的关系的图。
图2是设有覆盖片的本发明的指甲用贴剂的俯视图的一例。
图3是设有覆盖片的本发明的指甲用贴剂的剖面图的一例。
图4是将设有覆盖片的本发明的指甲用贴剂做成片状结构的俯视图的一例。
符号说明
1 支持体
2 乳膏
3 覆盖片
4 衬里
5 指甲用医药组合物
具体实施方式
本发明的指甲用医药组合物,含有抗真菌药、烷基吡咯烷酮或其衍生物和交联型含水凝胶作为必须成分。
作为用于本发明的指甲用医药组合物中的抗真菌药,可列举出兰诺康唑、联苯苄唑、奈康唑、氯康唑、克霉唑、酮康唑、艾康唑(iconazole)、益康唑、奥昔康唑、硫康唑、咪康唑、异康唑、噻康唑、氟康唑、伊曲康唑、卢立康唑等唑类抗真菌药,特比奈芬等烯丙基胺类抗真菌药,布替奈芬等苄胺类抗真菌药,托萘酯等硫代氨基甲酸类抗真菌药,阿莫罗芬等吗啉类抗真菌药,制霉菌素等多烯大环内酯类抗真菌药,十一碳烯酸、水杨酸、环吡酮胺、西卡宁、三环萜醛、木焦油、利拉萘酯、硝吡咯菌素、灰黄霉素、萘替芬、癣可净等其它抗真菌药和药理学上允许的它们的盐等。
在本发明中,在这些抗真菌药中优选水难溶性的抗真菌药,具体可以列举兰诺康唑、联苯苄唑、奈康唑、氯康唑、克霉唑、酮康唑、硝酸艾康唑、硝酸益康唑、硝酸奥昔康唑、硝酸硫康唑、硝酸咪康唑、硝酸异康唑、噻康唑、氟康唑、伊曲康唑、盐酸特比奈芬、托萘酯、盐酸阿莫罗芬、制霉菌素。在这些水难溶性抗真菌药中,从具有广谱抗菌谱、抗菌活性高的方面出发,特别优选使用兰诺康唑、联苯苄唑、盐酸特比奈芬、盐酸布替奈芬、盐酸阿莫罗芬等。另外,在本发明中,所谓的水难溶性是指按照日本药局方的性状项目中的溶解性评价法评价对水的溶解性时,在难溶程度以上的难以溶解的性质,即对水的溶解度为0.01g/ml以下。
指甲用医药组合物中的这些抗真菌药的含量,可根据抗真菌药种类适当决定,不过一般相对于指甲用医药组合物的总量为1~10质量%(以下仅称为“%”),优选1~5%。
另一方面,作为用于本发明的指甲用医药组合物中的烷基吡咯烷酮或其衍生物(以下称作“烷基吡咯烷酮类”),可以列举例如选自N-甲基-2-吡咯烷酮、N-(2-羟乙基)吡咯烷酮、N-辛基吡咯烷酮、N-乙烯基-2-吡咯烷酮、2-吡咯烷酮、3-吡咯烷酮等烷基吡咯烷酮或其衍生物中的烷基吡咯烷酮类的1种或2种以上。在这些烷基吡咯烷酮类中,优选增进指甲透过性的N-甲基-2-吡咯烷酮。
指甲用医药组合物中的这些烷基吡咯烷酮类的含量优选1~20%,更优选1~10%。如果低于该范围,特别是配合有水难溶性的抗真菌药时指甲用医药组合物的溶解性降低,另外,如果高于该范围,则制剂稳定性降低。
本发明的指甲用医药组合物残留的必须成分即交联型含水凝胶,是通过将水溶性交联性高分子在水存在下用交联剂交联得到的物质。另外,水溶性交联性高分子是指水溶性的高分子,通过交联剂交联、凝胶化的高分子。
作为被交联的水溶性交联性高分子,可以列举例如选自聚丙烯酸部分中和物(例如,钠含量10~19%)、聚丙烯酸、聚丙烯酸钠、羧甲基纤维素钠、明胶中的水溶性交联性高分子的一种或两种以上。这些水溶性交联性高分子中,优选聚丙烯酸和/或聚丙烯酸(部分中和物)。这些水溶性交联性高分子在指甲用医药组合物中的含量,可根据对水的溶解性、与后述的交联剂(特别是铝化合物)的反应性、贴附指甲时的粘结力适当决定,不过一般优选1~30%,更优选1~20%,如果低于该范围,则制剂对指甲的粘着性降低,如果高于该范围,则从指甲上的剥离性降低。
作为用来交联上述水溶性交联性高分子以形成交联型含水凝胶的交联剂,可以使用各种多价金属的盐,例如铝化合物、镁化合物、钙化合物,分子中至少具有2个以上环氧基的化合物等。该交联剂在指甲用医药组合物中的含量优选0.1~1%,更优选0.1~0.5%。
为了得到交联型含水凝胶,指甲用医药组合物中必须的水的含量优选20~80%,更优选30~50%。
另外,在本发明的指甲用医药组合物中,作为抗真菌药的溶解(助)剂,可以配合多元醇。作为这样的多元醇,可以列举选自聚乙二醇、丙二醇等二醇类,甘油、双甘油、山梨醇中的多元醇的一种或两种以上。其中优选是二醇类,具体可以列举平均分子量为200、300、400、600、1000、1500、1540、4000、6000、20000、35000的聚乙二醇、丙二醇、二丙二醇、聚丙二醇、1,3-丁二醇、1,4-丁二醇、异丁二醇等,特别优选平均分子量为200、300、400、600、1000、1500的聚乙二醇。这些多元醇在指甲用医药组合物中的含量优选1~50%,更优选20~50%。
进而,本发明的指甲用医药组合物中,除了上述成分外,可以添加不通过交联剂进行交联而具有增强粘结作用的粘结增强剂。作为这样的粘结增强剂,可列举丙烯酸淀粉酯、聚乙烯醇、羧基乙烯基聚合物、羟丙基纤维素、羧甲基纤维素、酪蛋白酸钠、羟甲基纤维素、羟乙基纤维素、羟丙基甲基纤维素、甲基纤维素、聚乙烯吡咯烷酮、海藻酸钠和甲基乙烯醚·马来酸酐共聚物,它们可以使用一种或两种以上。这些粘结增强剂中,优选羧甲基纤维素和/或羟丙基纤维素,特别是使用聚乙烯酸和/或聚乙烯酸部分中和物作为上述水溶性交联性高分子时,组合羧甲基纤维素和/或羟丙基纤维素,由此成型性良好,故优选。这些粘结增强剂在指甲用医药组合物中的含量优选1~10%,更优选1~5%。
另外,在本发明的指甲用医药组合物中,根据需要还可以加入pH调整剂、湿润剂、增稠剂、湿润调整剂、吸收促进剂、表面活性剂、防腐剂、抗氧化剂、香料等各种的任意成分。
作为pH调整剂,可以使用乳酸、柠檬酸、苹果酸、酒石酸、草酸、安息香酸、乙醇酸、乙酸、丙酸、琥珀酸、丙二酸等有机酸。这些pH调整剂可以单独使用1种或使用2种以上。从制剂稳定性方面考虑,可以添加这些pH调整剂以使基剂的pH达到3.5~6.5左右。
作为增稠剂,可以列举阿拉伯树胶粉末、糊精、黄蓍胶粉末、果胶、黄原胶、甘油、滑石等。
作为湿润调整剂可以列举轻质硅酸酐、dl-吡咯烷酮羧酸钠等。
作为吸收促进剂可以列举尿素、二甲亚砜、水杨酸乙二醇酯、克罗米通、苄醇、肉豆蔻酸异丙醇酯等。
作为表面活性剂可以列举聚山梨酯、聚氧乙烯氢化蓖麻油、蔗糖脂肪酸酯、月桂醇硫酸钠、硬脂醇、癸二酸二乙酯、单硬脂酸聚乙二醇酯等。
在不损害本发明的效果的范围内,可以适当地含有其它的防腐剂、抗氧化剂、香料。
本发明的指甲用医药组合物可如下制造,即,将作为必须成分的抗真菌药、烷基吡咯烷酮类和构成交联型含水凝胶的水溶性交联性高分子、交联剂、水、根据需要的上述的任意成分溶解或分散并混合而制成。具体地,可以通过在抗真菌药、烷基吡咯烷酮类、水溶性交联性高分子、交联剂、水中加入任意成分,充分混合后,加入pH调整剂,再次充分混合而制成。
在该指甲用医药组合物的制造中,优选使药剂即抗真菌药事先溶解来使用。具体地,优选在烷基吡咯烷酮类中溶解抗真菌药后,向其中加入其它成分充分混合,然后加入pH调整剂,再次充分混合而制造。
上述这样得到的指甲用医药组合物可以做成凝胶剂、乳膏剂、软膏剂、液剂、洗剂、乳剂、贴剂等剂型,在这些剂型中优选贴剂。
具体地,为了将本发明的指甲用医药组合物做成贴剂,首先将本发明的指甲用医药组合物利用如展开机在适当的支持体上涂布、展开,进而根据需要,可以将可剥离的衬里等贴合在应用面侧,用模具等打孔成贴附指甲用的大小。另外,进而为了提高对应用部位(患处)的固定性,优选在上述贴剂的支持体上的、与涂布、展开了指甲用医药组合物的面的相反侧,设置设有粘合层的覆盖片。
涂布、展开有指甲用医药组合物的支持体,优选不会对药物释放产生影响的物质,可以使用伸缩性和非伸缩性的任意一种支持体。另外,该支持体因为需要密封指甲来提高对指甲的渗透性,所以优选使用不透水性的原材料。具体地,作为支持体可以列举无纺布、布、薄膜(含片材)、多孔质体、发泡体、纸、在无纺布或布上层压有薄膜的叠层体等。作为这些支持体的原材料,可以列举无纺布(化纤布)、短纤维平纹细布、氯乙烯膜、聚乙烯膜、聚氨酯·聚氯乙烯共聚膜、聚氨酯膜、聚丙烯膜、聚酯膜、聚对苯二甲酸乙二酯类(PET)、醋酸纤维素、乙基纤维素、塑性醋酸乙烯-氯乙烯共聚物、尼龙、乙烯-醋酸乙烯酯共聚物、塑性聚氯乙烯、聚偏氯乙烯、铝等。
另外,因为需要防止水分从指甲用医药组合物中蒸发,所以用于覆盖指甲用医药组合物的衬里优选不透水性的原材料。具体地可以列举薄膜(含有片材)、多孔质体、发泡体等。作为这些衬里的原材料,可以列举短纤维平纹细布、氯乙烯膜、聚乙烯膜、聚氨酯·聚氯乙烯共聚膜、聚氨酯膜、聚丙烯膜、聚酯膜、聚对苯二甲酸乙二酯类(PET)、醋酸纤维素、乙基纤维素、塑性醋酸乙烯-氯乙烯共聚物、尼龙、乙烯-醋酸乙烯酯共聚物、塑性聚氯乙烯、聚偏氯乙烯、剥离纸(脱模纸)等。进而,为了调整剥离性可以进行轧纹加工、硅酮处理、电晕处理等。
进而,作为设置在涂布、展开有指甲用医药组合物的支持体上的覆盖片材质,可以列举无纺布、布、网、针织物、纱布、薄膜等,在这些中,优选不会引起固定部位的不透气或破裂、有某种程度的透气性的物质。作为具体的覆盖片原材料,可以列举聚酯(纤维)、聚乙烯(纤维)、聚丙烯(纤维)、人造丝、铜氨丝、麻等。另外,作为用于覆盖片粘合层的粘结剂,可以列举丙烯酸烷基酯等丙烯酸类、S-I-S共聚物等橡胶类、硅类等物质。
这样得到的本发明的指甲用医药组合物对指甲的渗透性优异,可以充分发挥抗真菌效果,因此,本发明的指甲用医药组合物,可适当利用于手指或脚趾的甲癣、指甲念珠菌病等疾病的治疗中,特别是可利用于手指或脚趾的指甲感染真菌的甲癣症的治疗中。具体地,利用了本发明的指甲用医药组合物的剂贴剂在用于治疗真菌症时,优选在手或脚的指甲患处每天贴附1~4个。
实施例
以下列举实施例和试验例进一步详细说明本发明,但本发明并不受这些实施例等的任何限制。
实施例1
指甲用医药组合物的制造(1):
使用表1的配方,根据下述制法制造本发明的指甲用医药组合物。
(制法)
将兰诺康唑溶解在N-甲基-2-吡咯烷酮中,向其中加入聚乙二醇、丙二醇后,加入聚丙烯酸部分中和物、干燥的氢氧化铝凝胶、轻质硅酸酐,充分搅拌以使其分散。
向分散后的该溶液中,每次少量地加入事先溶解在半量的纯化水中的聚乙烯醇的水溶液,充分混合。向其中再每次少量地加入溶解在剩余半量的纯化水中的乳酸,充分混合使其交联,得到指甲用医药组合物。
将得到的指甲用医药组合物,使用软膏刮刀在作为支持体的无纺布上展开涂布成100g/m2,在其上贴合聚丙烯膜以覆盖。将其裁成适当的大小,然后使用模具制成指甲贴附用,得到贴剂型的指甲用医药组合物(本发明品1)。
实施例2
指甲用医药组合物的制造(2):
除了将表1的配方的兰诺康唑换成克霉唑以及将聚乙烯醇换成羧基乙烯基聚合物外,使用与实施例1相同的制法,制造贴剂型的指甲用医药组合物(本发明品2)。
实施例3
指甲用医药组合物的制造(3):
除了将表1配方的兰诺康唑换成联苯苄唑,并添加了甘油外,使用与实施例1相同的制法,制造贴剂型的指甲用医药组合物(本发明品3)。并且,甘油与丙二醇一起添加。
比较例1
比较指甲用医药组合物的制造:
通过常规方法制造表1所示配方的贴剂型的比较指甲用医药组合物(比较品1)。
上述本发明品1~3和比较品1的配方列于表1中。
(配方)
表1
试验例1
使用牛蹄进行指甲透过性试验:
使用牛指甲(蹄),评价本发明品1和比较品1中的抗真菌药(兰诺康唑)的指甲透过性。如下进行试验,即,将牛蹄切割成厚度约1.0mm,将其夹入纵型的Franz cell中,在其上部放入本发明品1和比较品1的试验样品,在容器的一侧,放入等渗磷酸缓冲液(pH:7.4),每次测定时取样1.5mL,测定其中的抗真菌药量。将上述取的样用高效液相色谱(HPLC)(HPLCアイソクラテイツクシステム:日本分光社制)来进行抗真菌药量的定量。将实验开始到经过32个小时后抗真菌药的指甲累积透过量与经过时间的关系示于图1中。
如图1所示,本发明品1的指甲用医药组合物抗真菌药的累积透过量随着经过时间的增加而增加,可以确认抗真菌药随着时间渗透到指甲中。另一方面,比较品1的贴剂,抗真菌药的累积透过量相对于经过的时间,几乎没有变化。
试验例2
指甲中抗真菌药的浓度的测定:
对本发明品1和比较品1,在试验例1的指甲透过性试验结束后(经过32个小时后),从牛蹄切片的表面取走本发明品1和比较品1,用水和乙醇彻底擦拭,将该样品放入等渗磷酸缓冲液(pH:7.4)中,用水浴摇床(PERS ONAL-11:TAITEC公司制)振荡提取24小时,取出样品,取样后再次进行同样的提取操作。混合得到的提取液,将提取液中的抗真菌药与试验例1同样用HPLC进行定量分析。结果示于表2。
(结果)
表2
指甲中的浓度(μg/g指甲) | |
本发明品1 | 34.21 |
比较品1 | 9.31 |
如表2的结果所示,可以确认在试验开始经过32个小时后,使用本发明品1的指甲用医药组合物与使用比较品1相比,指甲中的抗真菌药的渗透量多。
试验例3
长期保存时抗真菌药稳定性的评价:
对本发明品1的指甲用医药组合物,使用以制造时作为100%的残余率来评价在50℃保存1个月和2个月时抗真菌药(兰诺康唑)的稳定性。结果示于表3。
(结果)
表3
保持率(%) | |
制造时 | 100.1 |
经过1个月后 | 98.8 |
经过2个月后 | 96.3 |
如表3的结果所示,本发明品的指甲用医药组合物即使长期间保存,也能将抗真菌药保持几乎与制造时相同,因此,可确认本发明的指甲用医药组合物即使长期保存,也可以稳定保持抗真菌药。
实施例4
指甲用医药组合物的制造(4):
使用表4的配方和下述的制法,制造本发明的指甲用医药组合物(本发明品4和本发明品5)。
(制法)
将溶解在N-甲基-2-吡咯烷酮和聚乙二醇中的兰诺康唑、水溶性高分子的一部分和甘油溶解在一部分纯化水中,向其中加入其它的配合成分,充分混合。进而,在其中加入其它成分并混合。最后加入剩余部分的纯化水和聚丙烯酸部分中和物,再混合至均匀,得到乳膏。将此乳膏均匀涂布到无纺布上,形成规定的形状后,包装,制成贴剂。
表4
上述所得的本发明品,使用试验例1中的牛蹄进行指甲透过性实验,结果如图1所示,抗真菌药的累积透过量随着经过时间的增加而增加,抗真菌药随着时间渗透到指甲中。
实施例5
指甲用医药组合物的制造(5):
在纵向22mm、横向75mm的聚酯(纤维)上,整体涂布作为粘合层的以丙烯酸2-乙基己酯为主要成分的丙烯酸类粘结剂制成覆盖片,将本发明品5的指甲用医药组合物的无纺布一侧贴附在覆盖片中央的粘合层,得到本发明的带覆盖片的指甲用医药组合物(本发明品6)。
试验例4
使用指甲用医药组合物和带覆盖片的指甲用医药组合物的贴附试验:
为了确认覆盖片的效果,使用本发明品5的指甲用医药组合物和本发明品6的带覆盖片的指甲用医药组合物,在下述试验条件下对志愿者进行试验。另外,基于下述评价标准对试验后的贴附性进行评价。结果示于表5。
试验条件
被试验者数:脚趾甲5名
手指甲4名
试验制剂:本发明品5(没有覆盖片)
本发明品6(有覆盖片)
贴附部位:脚(左右拇指的指甲)
手(左右拇指的指甲)
贴附时间:约8小时
评价基准:
内容: 评价: 分数
完全粘结 ◎ 3
一部分剥落 ○ 2
一半剥落 △ 1
剥落 × 0
表5
由表5可知,本发明品5具有一定的粘结性,手指甲的情况下,即使在睡觉时也没有剥落,不过,在脚趾甲的情况下,因为与寝具接触有可能剥落。另一方面,带覆盖片的本发明品6显示出不仅手指甲时不剥落,就连在脚上、在睡觉时也没有剥落,且制剂密合在患处,可期待得到充分的治疗效果。
产业上的可利用性
本发明的指甲用医药组合物可以提高对指甲的药物渗透性,使抗真菌效果得到充分发挥。
因此,本发明的指甲用医药组合物,可以期待作为在甲癣等指甲疾病的治疗上发挥效果的外用剂来利用。
Claims (11)
1.一种指甲用医药组合物,其特征在于,其含有抗真菌药、烷基吡咯烷酮或其衍生物和交联型含水凝胶。
2.根据权利要求1所述的指甲用医药组合物,抗真菌药是选自由兰诺康唑、联苯苄唑、奈康唑、氯康唑、克霉唑、酮康唑、艾康唑、益康唑、奥昔康唑、硫康唑、咪康唑、异康唑、噻康唑、氟康唑、伊曲康唑、卢立康唑、特比奈芬、布替奈芬、托萘酯、阿莫罗芬和制霉菌素或者药理学上允许的它们的盐等组成的组中的抗真菌药。
3.根据权利要求1或2所述的指甲用医药组合物,抗真菌药是水难溶性的。
4.根据权利要求1~3中的任一项所述的指甲用医药组合物,烷基吡咯烷酮或其衍生物是选自由N-甲基-2-吡咯烷酮、N-(2-羟乙基)吡咯烷酮、N-辛基吡咯烷酮、N-乙烯基-2-吡咯烷酮、2-吡咯烷酮和3-吡咯烷酮组成的组中的烷基吡咯烷酮或它们的衍生物的一种或两种以上。
5.根据权利要求1~4中的任一项所述的指甲用医药组合物,交联型含水凝胶是将水溶性交联性高分子在水的存在下使用多价金属的盐进行交联而成的物质。
6.根据权利要求5所述的指甲用医药组合物,水溶性交联性高分子是选自由聚丙烯酸部分中和物、聚丙烯酸、聚丙烯酸钠、羧甲基纤维素钠、明胶组成的组中的水溶性交联性高分子的一种或两种以上。
7.根据权利要求1~6中的任一项所述的指甲用医药组合物,还含有多元醇。
8.根据权利要求7所述的指甲用医药组合物,多元醇是选自由平均分子量为200、300、400、600、1000、1500、1540、4000、6000、20000和35000的聚乙二醇、丙二醇、二丙二醇、聚丙二醇、1,3-丁二醇、1,4-丁二醇、异丁二醇、甘油、双甘油和山梨醇组成的组中的多元醇的1种或2种以上。
9.根据权利要求1~8中的任一项所述的指甲用医药组合物,进一步含有由丙烯酸淀粉酯、聚乙烯醇、羧基乙烯基聚合物、羟丙基纤维素、羧甲基纤维素、酪蛋白酸钠、羟甲基纤维素、羟乙基纤维素、羟丙基甲基纤维素、甲基纤维素、聚乙烯吡咯烷酮、海藻酸钠和甲基乙烯基醚·马来酸酐共聚物组成的组中的粘结增强剂的1种或2种以上。
10.一种指甲用贴剂,将权利要求1~9中的任一项所述的指甲用医药组合物在支持体上涂布、展开而形成。
11.根据权利要求10所述的指甲用贴剂,在支持体上的与涂布、展开有指甲用医药组合物的面的相反一侧,进一步贴附了设有粘合层的覆盖片。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP378441/2005 | 2005-12-28 | ||
JP2005378441 | 2005-12-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN101351227A true CN101351227A (zh) | 2009-01-21 |
Family
ID=38228159
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA2006800496424A Pending CN101351227A (zh) | 2005-12-28 | 2006-12-26 | 指甲用医药组合物 |
Country Status (6)
Country | Link |
---|---|
US (2) | US9579297B2 (zh) |
EP (1) | EP1970076A4 (zh) |
JP (1) | JP5290582B2 (zh) |
KR (1) | KR20080080355A (zh) |
CN (1) | CN101351227A (zh) |
WO (1) | WO2007077806A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102423293A (zh) * | 2011-01-28 | 2012-04-25 | 舒泰神(北京)生物制药股份有限公司 | 一种硝酸奥昔康唑的微乳凝胶制剂 |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007102243A1 (ja) | 2006-03-08 | 2007-09-13 | Nihon Nohyaku Co., Ltd. | 外用の医薬組成物 |
EP2025337B1 (en) | 2006-03-08 | 2014-09-10 | Nihon Nohyaku Co., Ltd. | Pharmaceutical composition for external use |
RU2423128C2 (ru) | 2006-03-08 | 2011-07-10 | Нихон Нохияку Ко., Лтд. | Фармацевтическая композиция для наружного применения |
WO2009031642A1 (ja) | 2007-09-05 | 2009-03-12 | Pola Pharma Inc. | 医薬組成物 |
WO2009031643A1 (ja) | 2007-09-05 | 2009-03-12 | Pola Pharma Inc. | 抗真菌組成物 |
EP2191828B1 (en) * | 2007-09-05 | 2016-08-10 | Pola Pharma Inc. | Antifungal pharmaceutical composition |
JP5319950B2 (ja) * | 2008-04-08 | 2013-10-16 | 帝國製薬株式会社 | 塩酸ブテナフィン含有水性貼付剤 |
KR101004648B1 (ko) * | 2008-08-20 | 2011-01-03 | 엄관수 | 네일 팩 |
JP5654497B2 (ja) * | 2009-02-13 | 2015-01-14 | トピカ ファーマシューティカルズ,インコーポレイテッド | 抗真菌製剤 |
JP5688405B2 (ja) | 2009-04-09 | 2015-03-25 | 株式会社ポーラファルマ | 抗真菌医薬組成物 |
JP5688406B2 (ja) | 2009-04-09 | 2015-03-25 | 株式会社ポーラファルマ | 抗真菌医薬組成物 |
WO2011024620A1 (en) | 2009-08-25 | 2011-03-03 | Pola Pharma Inc. | Antimycotic pharmaceutical composition |
JP2011051966A (ja) * | 2009-09-03 | 2011-03-17 | Daiya Seiyaku Kk | 爪白癬治療用貼付剤 |
WO2011118683A1 (ja) * | 2010-03-25 | 2011-09-29 | 東洋化学株式会社 | 医用貼付剤 |
ES2369101B2 (es) | 2010-05-07 | 2012-08-02 | Universidade De Santiago De Compostela | Sistema farmacéutico acuoso para la administración de fármacos en las uñas. |
EP2952208A1 (en) | 2014-06-04 | 2015-12-09 | Universidade de Santiago de Compostela | Hydroalcoholic system for nail treatment |
JP6701978B2 (ja) * | 2015-06-04 | 2020-05-27 | 大正製薬株式会社 | 外用組成物 |
US10426744B2 (en) * | 2016-04-08 | 2019-10-01 | Harrow Health, Inc. | Anti-fungal compositions for treating nails and methods for fabricating and using thereof |
JP6310977B2 (ja) * | 2016-09-07 | 2018-04-11 | 株式会社日本総合研究所 | 爪用シール及びシールシート |
US20210212994A1 (en) * | 2017-02-28 | 2021-07-15 | Temple University-Of The Commonwealth System Of Higher Education | Novel Econazole Nitrate Medical Patch and Methods of Use Thereof |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3932653A (en) * | 1974-12-19 | 1976-01-13 | Nelson Research & Development Co. | Composition and method for topical administration of griseofulvin |
JPS5287239A (en) * | 1976-01-09 | 1977-07-20 | Nelson Res & Dev | Local antibiotic composition |
JPS58162514A (ja) * | 1982-03-19 | 1983-09-27 | Sumitomo Chem Co Ltd | 外用ゲル製剤 |
AU599064B2 (en) | 1985-11-04 | 1990-07-12 | Dermatological Products Of Texas | Film-forming, pharmaceutical vehicles for application of medicaments to nails, pharmaceutical compositions based on those vehicles, and methods of using same |
JPS62123112A (ja) * | 1985-11-22 | 1987-06-04 | Sunstar Inc | 軟膏基剤 |
FR2613227B1 (fr) | 1987-04-01 | 1990-12-28 | Oreal | Compositions pharmaceutiques a base de nitrate de miconazole ou de nitrate d'econazole dans le traitement des infections fongiques des ongles |
US5160743A (en) * | 1988-04-28 | 1992-11-03 | Alza Corporation | Annealed composition for pharmaceutically acceptable drug |
FR2673537B1 (fr) * | 1991-03-08 | 1993-06-11 | Oreal | Utilisation d'agents de penetration hydrophiles dans les compositions dermatologiques pour le traitement des onychomycoses, et compositions correspondantes. |
US5391367A (en) * | 1993-07-28 | 1995-02-21 | Pfizer Inc. | Antifungal nail solution |
DE4337945A1 (de) | 1993-11-06 | 1995-05-11 | Labtec Gmbh | Pflaster zur Behandlung von Nagelmykosen |
JP4253047B2 (ja) | 1996-09-27 | 2009-04-08 | 杏林製薬株式会社 | 被膜形成性抗真菌剤組成物 |
JP4227677B2 (ja) | 1996-12-10 | 2009-02-18 | 杏林製薬株式会社 | 被膜形成性抗真菌剤組成物 |
JP4275768B2 (ja) * | 1998-06-18 | 2009-06-10 | 久光製薬株式会社 | 水性粘着膏体 |
US6294192B1 (en) | 1999-02-26 | 2001-09-25 | Lipocine, Inc. | Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents |
CN1422142A (zh) | 2000-02-16 | 2003-06-04 | 本特利药品公司 | 药用组合物 |
US20030072807A1 (en) * | 2000-12-22 | 2003-04-17 | Wong Joseph Chung-Tak | Solid particulate antifungal compositions for pharmaceutical use |
US6585963B1 (en) | 2001-02-15 | 2003-07-01 | Watson Pharmaceuticals, Inc. | Nail compositions and methods of administering same |
EP1390085B1 (en) * | 2001-05-01 | 2009-08-05 | A.V. Topchiev Institute of Petrochemical Synthesis | Hydrogel compositions |
US7615238B2 (en) * | 2001-09-04 | 2009-11-10 | Trommsdorff GmbH & Co. KG Arzneimitttel | Plaster for the treatment of dysfunctions and disorders of nails, comprising sertaconazole |
JP2003252798A (ja) | 2002-02-28 | 2003-09-10 | Shiseido Co Ltd | 抗菌ゲル製剤 |
BRPI0309765B8 (pt) | 2002-05-01 | 2021-05-25 | Mcneil Ppc Inc | composições em gel antifúngicas lubrificantes não-irritantes e aquecedoras |
US6846837B2 (en) * | 2002-06-21 | 2005-01-25 | Howard I. Maibach | Topical administration of basic antifungal compositions to treat fungal infections of the nails |
JP2004083439A (ja) * | 2002-08-23 | 2004-03-18 | Ss Pharmaceut Co Ltd | 爪用抗真菌外用剤 |
WO2019152695A1 (en) * | 2018-01-31 | 2019-08-08 | Texas Tech University System | Films and composites and methods of production and use |
-
2006
- 2006-12-26 JP JP2007552927A patent/JP5290582B2/ja active Active
- 2006-12-26 WO PCT/JP2006/325842 patent/WO2007077806A1/ja active Application Filing
- 2006-12-26 CN CNA2006800496424A patent/CN101351227A/zh active Pending
- 2006-12-26 EP EP06843226A patent/EP1970076A4/en not_active Withdrawn
- 2006-12-26 KR KR1020087016134A patent/KR20080080355A/ko not_active Application Discontinuation
- 2006-12-26 US US12/159,591 patent/US9579297B2/en active Active
-
2017
- 2017-01-06 US US15/399,828 patent/US20170112780A1/en not_active Abandoned
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102423293A (zh) * | 2011-01-28 | 2012-04-25 | 舒泰神(北京)生物制药股份有限公司 | 一种硝酸奥昔康唑的微乳凝胶制剂 |
Also Published As
Publication number | Publication date |
---|---|
JP5290582B2 (ja) | 2013-09-18 |
JPWO2007077806A1 (ja) | 2009-06-11 |
EP1970076A4 (en) | 2012-12-12 |
US20090202602A1 (en) | 2009-08-13 |
US9579297B2 (en) | 2017-02-28 |
WO2007077806A1 (ja) | 2007-07-12 |
US20170112780A1 (en) | 2017-04-27 |
KR20080080355A (ko) | 2008-09-03 |
EP1970076A1 (en) | 2008-09-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101351227A (zh) | 指甲用医药组合物 | |
KR100640039B1 (ko) | 세르타코나졸을 포함하며, 손발톱의 기능장애와 질환을치료하기 위한 플라스터 | |
KR100757611B1 (ko) | 손발톱 성장의 기능장애와 질환을 치료하기 위한 플라스터 | |
EP2387394B1 (en) | Transdermal administration of tamsulosin | |
US8404277B2 (en) | Matrix-type transdermal drug delivery system and preparation method thereof | |
JP6359032B2 (ja) | 経皮薬物送達用のマルチポリマー組成物 | |
AU2002361825A1 (en) | Plaster for the treatment of dysfunctions and disorders of nail growth | |
JP2002512187A (ja) | 爪真菌病の処置のための局所製剤 | |
JP2002363070A (ja) | 経皮吸収貼付剤 | |
JPH07206711A (ja) | 爪白癬治療用組成物 | |
WO1996011710A1 (fr) | Preparation externe pour onychomycose | |
KR20120093239A (ko) | 디클로페낙 나트륨 함유 수성 패치 | |
JP3269822B2 (ja) | 4−置換イミダゾール含有経皮投与用医薬組成物 | |
JP5059408B2 (ja) | 爪用外用剤 | |
JP5319950B2 (ja) | 塩酸ブテナフィン含有水性貼付剤 | |
CN110139641A (zh) | 外用组合物 | |
US7615238B2 (en) | Plaster for the treatment of dysfunctions and disorders of nails, comprising sertaconazole | |
JPH10120593A (ja) | 抗真菌外用剤 | |
US20040258739A1 (en) | Plaster for the treatment of dysfunctions and disorders of nails | |
KR20090129623A (ko) | 헤파린 및 디글로페낙을 함유한 국소용 첩부제 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C12 | Rejection of a patent application after its publication | ||
RJ01 | Rejection of invention patent application after publication |
Open date: 20090121 |